Welcome to our dedicated page for VERADERMICS news (Ticker: MANE), a resource for investors and traders seeking the latest updates and insights on VERADERMICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VERADERMICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VERADERMICS's position in the market.
Veradermics (NYSE: MANE) reported Q4 and full-year 2025 results and clinical progress. The company closed an upsized IPO raising approximately $294.8M in February 2026; cash was $141.9M as of Dec 31, 2025, and combined proceeds are expected to fund operations into 2029.
Enrollment completed in male registrational trials Study 302 and Study 304 (>1,000 male participants); topline readouts expected in 1H 2026 (Study 302) and 2H 2026 (Study 304). Study 306 in females is enrolling (>500 planned). R&D, G&A, and net losses widened in 2025 versus 2024.
Veradermics (NYSE: MANE) will present three abstracts at the 2026 American Academy of Dermatology Annual Meeting in Denver, Mar 27–31, 2026, reporting blinded investigator comparisons of an extended‑release oral minoxidil (VDPHL01) versus topical and immediate‑release formulations and social listening analyses of patient experiences with pattern hair loss.
The presentations include an e-poster on VDPHL01 efficacy and two posters summarizing social listening research across hundreds of thousands of online conversations, with scheduled times on Mar 27 at the Colorado Convention Center.
Veradermics (NYSE: MANE) announced management will attend two investor conferences in Miami in March.
CEO Reid Waldman, M.D. will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 4:20 p.m. ET. A live webcast and a ~30-day replay will be available on the company’s investor Events page.
Forgent Power Solutions (NYSE: FPS) marked its early February IPO by ringing the NYSE Opening Bell on February 12, 2026, after shares rose 22% since trading began. The NYSE pre-market update noted broader market moves after a 130,000 jobs print from the Bureau of Labor Statistics.
The NYSE also highlighted Veradermics (NYSE: MANE) and announced a new NYSE Texas Advisory Board to support listings and trading in the Southwestern U.S.
Veradermics (NYSE: MANE) completed enrollment across both Phase 3 male trials of oral VDPHL01, totaling approximately 1,000+ male participants. Topline data from the initial '302' trial is expected in H1 2026, with the '304' confirmatory male study topline in H2 2026. The company is also recruiting for a female Phase 2/3 trial.
VDPHL01 is an extended-release oral minoxidil formulation designed to minimize plasma concentration spikes associated with cardiac activity while delivering sustained hair‑follicle exposure.
Veradermics (NYSE: MANE) closed its upsized initial public offering of 17,339,294 common shares at $17.00 per share, including the full exercise of the underwriters' 2,261,647-share option. Gross proceeds were approximately $294.8 million before underwriting discounts, commissions, and expenses.
All shares were sold by Veradermics and began trading on the New York Stock Exchange on February 4, 2026. Jefferies, Leerink Partners, Citigroup, and Cantor acted as joint book-running managers. Registration statements were filed with and declared effective by the SEC.
Veradermics (NYSE: MANE) priced an upsized initial public offering of 15,077,647 shares at $17.00 per share, raising approximately $256.3 million in gross proceeds before fees. The company expects NYSE trading to begin on February 4, 2026 and closing on February 5, 2026, subject to customary conditions.
The underwriters received a 30-day option to purchase up to an additional 2,261,647 shares. Jefferies, Leerink Partners, Citigroup, and Cantor are joint book-running managers.